Back to results
US 2011/0033444 A1Published application
Genetic variants in a hypertension susceptibility gene Stk39 and uses thereof
OwnerYen-Pei Chang, Alan R. Shuldiner +4inventors
InventorsYen-Pei Chang, Alan R. Shuldiner, Braxton D. Mitchell, Patrick F. McArdle, Ying Wang, Sarah E. Dorff
Life of this patent
Estimating the term…
Abstract
The present invention is drawn to diagnosis and treatment of essential hypertension. In this regard, the present invention discloses genetic variants in a hypertension susceptibility gene Stk39 and its use in the diagnosis and treatment of essential hypertension.
Claims20
A method of determining susceptibility of an individual to developing essential hypertension, comprising:
- detecting at least one single nucleotide polymorphism in the Stk39 gene in a sample from the individual, wherein the presence of said single nucleotide polymorphism in the sample indicates that said individual is susceptible to develop essential hypertension.
A method of treating an individual with essential hypertension, comprising:
- administering pharmacologically effective amounts of a compound that inhibits at least one single nucleotide polymorphism in Stk39 at the nucleic acid level and/or inhibits at least one protein encoded by a single nucleotide polymorphism in Stk39 to the individual, thereby treating the individual with essential hypertension.
A method of treating an individual with essential hypertension, comprising:
- administering pharmacologically effective amounts of an anti-hypertensive drug to the individual, wherein said individual has at least one single nucleotide polymorphism in Stk39 gene, thereby treating the individual with essential hypertension.
Dependencies are inferred from the claim text.